ARTICLE | Clinical News
Xeomin incobotulinumtoxinA regulatory update
January 4, 2016 8:00 AM UTC
FDA approved an sBLA from Merz for Xeomin incobotulinumtoxinA to treat upper limb spasticity in adults. Xeomin is marketed in the U.S. to treat cervical dystonia, blepharospasm and glabellar lines. Th...